#65. Orbiting around Big Pharma

#65. Orbiting around Big Pharma

In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharmaceutical data, advanced predictive models, federated learning, and large-scale compute. On the positive side, platforms like TuneLab could help biotech companies derisk drug assets earlier, improve safety and pharmacokinetic predictions, reduce wasted experiments, and give smaller teams access to capabilities once reserved for Big Pharma. At the same time, this new model raises important questions about scientific independence, hidden bias, IP protection, and whether corporate AI platforms could become soft gatekeepers for what counts as a promising drug candidate. The best path forward is not to reject these platforms, but to use them wisely: as acceleration and second-opinion tools, complemented by open benchmarks, independent validation, human-relevant disease models, transparent governance, and mechanism-aware scientific judgment. Produced by Dr. Jake Chen.

#64. Foundation Models

In this episode, we explore the surge of foundation models (FMs) within pharmaceutical research, noting that over 200 such models were published by early 2025. Unlike traditional task-specific AI, these versatile algorithms are pre-trained on massive datasets to identify broad biological patterns before being refined for specialized functions. We detail how FMs are currently applied to transcriptomics, protein structures, and pathology imaging to enhance the speed and efficiency of drug discovery. Despite hurdles like data scarcity and technical "hallucinations," the source envisions a future where automated workflows use these models to identify drug targets and design molecules. This transition suggests a shift toward a "lab-in-the-loop" paradigm, where AI predictions and experimental results continuously optimize one another. Ultimately, the text argues that FMs possess transformative potential to modernize the historically slow and expensive process of creating new medicines. Produced by Dr. Jake Chen.

#63. The Era of NAMs

This podcast explores the transformative shift toward New Approach Methodologies (NAMs), which utilize human-relevant experimental and computational systems to modernize drug discovery and biomedical research. Major federal initiatives from the NIH and FDA are establishing a robust infrastructure for these technologies, moving them from peripheral alternatives to central organizing principles in regulatory science. The sources highlight how AI-driven integration of in vitro assays, such as organoids and tissue chips, with in silico modeling can significantly enhance the accuracy of safety and efficacy predictions. A featured case study on liver injury demonstrates that combining deep learning with human cell data provides more reliable results than traditional animal testing. Ultimately, the transition focuses on creating evidence-based ecosystems in which the choice of model is determined by its scientific fitness for a specific context of use. Growing policy alignment and FAIR data standards are currently paving the way for a faster, more ethical, and clinically predictive translational corridor. Produced by Dr. Jake Chen.

#62. Predicting Toxicity

In this episode, we investigate the significant evolution of AI-driven toxicity prediction, detailing how the field has shifted from simple statistical models to sophisticated deep learning and multimodal systems. It highlights a variety of computational tools, distinguishing between modern machine learning platforms like ProTox 3.0 and established regulatory-facing frameworks such as the OECD QSAR Toolbox. We emphasize that while these technologies accelerate drug discovery and chemical safety assessments, their reliability varies greatly depending on the specific biological endpoint and data quality. Furthermore, we advocate for a rigorous validation workflow that combines structural analysis with biological response data and expert human judgment. Ultimately, we explore the field's future, noting the emerging role of large language models and the ongoing challenge of translating in silico results into human-relevant safety outcomes. Produced by Dr. Jake Chen.

#61. AI Era Evidence Flywheel

In this episode, Dr. Jake Chen provides his narrative review and advocates for a fundamental shift in pharmaceutical research, moving away from inefficient trial-and-error toward an AI-augmented scientific discipline. The text outlines 12 core principles to transform drug discovery into a mechanism-aware system that prioritizes causal target biology, early safety prediction, and patient-centered strategies. Instead of using artificial intelligence simply to increase speed, Chen argues that these tools should reduce uncertainty and help researchers respect the fundamental laws of biology and chemistry. The source provides a comprehensive operational framework, including a decision-centric "evidence flywheel" and specific governance checklists for ensuring regulatory-grade credibility. Ultimately, the author suggests that the industry's future depends on human-AI collaboration, in which technology enhances rather than replaces rigorous scientific judgment. Produced by Dr. Jake Chen.